Navigation Links
Array BioPharma Reports Financial Results for the Third Quarter of Fiscal 2013
Date:5/6/2013

ay, June 1, 2:30 – 2:45 pm CDTIn addition, five scientific posters will be presented by AstraZeneca on selumetinib in the following cancers:  pancreatic cancer, BRAF-mutant melanoma, KRAS-mutant non-small cell lung cancer and KRAS-mutant colorectal cancer.

Initiated New Discovery Collaboration - Global Blood TherapeuticsArray and Global Blood Therapeutics initiated a multi-target drug discovery collaboration to identify small molecule lead compounds targeting chronic blood-based diseases. Array will develop assays and screen its proprietary lead generation library of 300,000 small molecules to identify both active site and allosteric modulators of certain Global Blood targets. Array's library will allow for rapid hit confirmation and subsequent lead optimization.

Appointed Chief Medical Officer – Michael N. Needle , M.D.Array appointed Michael N. Needle , M.D., to the position of Chief Medical Officer.  Dr. Needle, a board certified hematologist / oncologist, will oversee clinical development across Array's pipeline.  His deep industry experience includes prominent roles on the development of important oncology and hematology drugs including Erbitux® (cetuximab), Revlimid and Pomalyst.  He most recently served as the Chief Medical Officer of the Multiple Myeloma Research Foundation and Consortium (MMRF).  Prior to his tenure at MMRF, he held multiple Vice President level positions at Celgene.  Dr. Needle also served as the Vice President of Clinical Affairs at ImClone Systems Incorporated.  He did his fellowship in Pediatric Hematology / Oncology at the Children's Hospital Medical Center and the Fred Hutchinson Cancer Research Center of the University of Washington and the University of Texas M.D. Anderson Cancer Center.  Dr. Needle has held faculty positions at the University of Pennsylvania and Columbia University and received hi
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... A new Manhattan Research study, ... finds that members of pharmacy and therapeutics ... and pharmacy benefits managers (PBMs) are shifting the ... of formulary decision makers report that they are ... decision making process today than a year ago. ...
(Date:7/14/2014)...  Clinicians at a leading cancer center in ... first in the country to commence advanced lung, ... Clinac® medical linear accelerator from Varian Medical Systems ... High Intensity Mode dose delivery capability, which is ... treatment times and deliver stereotactic body radiotherapy and ...
(Date:7/14/2014)... 14, 2014  Patients and patient advocates are rallying ... and other major pharmacy benefit managers (PBMs) begin unprecedented ... impact millions of patients who rely on compounded medicines ... pain from cancer, diabetes and other illnesses. Express Scripts ... on July 15. In a matter of ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... SOUTHAMPTON, England, June 29 Vantia ... drugs,targeting large, underserved medical markets, announces positive results ... development compound VA106483 for,nocturia. The trial showed that ... sustained anti-diuretic effect in patients, as determined by,increased ...
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
Cached Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4
(Date:7/14/2014)... July 14, 2014 The North America ... in North America with analysis and forecast of revenue. ... grow from around $273.1 million in 2013 to $490.1 ... 2013 to 2018. , Browse through the TOC of ... idea of the in-depth analysis provided. This also provides ...
(Date:7/14/2014)... Employers looking to lower their ... more benefit options must understand how purchasing benefits ... are the future of employee benefits. , Horizon ... BCBSNJ) is offering a free webinar, The Future ... Options, to demonstrate how HorizonSelect, its private online ...
(Date:7/14/2014)... Continuing a steady trend of growth in the ... of first-quarter success with Orange Regional Medical Center, Nexus ... by CEO and President Dr. Virginia Feldman – has ... members. Robert Poltenovage has joined the Nexus ... LPN and Angelica D’Amico have joined the Nexus Health ...
(Date:7/14/2014)... The European Lecithin Market report explains ... and projection of revenue. The Lecithin Market in Europe ... 2012 to $315.9 million by 2019, at a CAGR ... the TOC of the European Lecithin Market report, to ... also provides a glimpse of the segmentation in the ...
(Date:7/14/2014)... use of antibiotics is still prevalent among terminal patients ... despite little evidence that the medications improve symptoms or ... effects. , The use of antibiotics is so engrained ... discharged from hospitals directly to a hospice program leave ... one fourth of them don,t have a documented infection ...
Breaking Medicine News(10 mins):Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 2Health News:The North America Biostimulant Market is Expected to Reach $490.1 Million by 2018 - New Report by MicroMarket Monitor 3Health News:No Cost Employer Webinar to Demonstrate How Private Exchanges Can Lower Benefit Costs While Increasing Options for Employees 2Health News:Nexus Health Resources Continues Growth, Outstanding Health Care Coordination With Addition of Three New Team Members 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 2Health News:The Lecithin Market in Europe is Expected to Reach $315.9 Million by 2019 - New Report by MicroMarket Monitor 3Health News:Antibiotic use prevalent in hospice patients despite limited evidence of its value 2
... , TAMPA, Fla. , Jan. ... the United States Preventative Task Force (USPTF), the Obesity Action ... add health insurance coverage of the recommended childhood obesity treatments. ... treating childhood obesity in moderate to intensive programs helps children ...
... , MORRISTOWN, N.J. , Jan. 19 ... a leading specialty pharmaceutical company, today confirmed that its subsidiary, ... (ANDA) with the U.S. Food and Drug Administration (FDA) seeking ... the expiration of U.S. Patent No. 5,827,529.  Watson,s lidocaine topical ...
... , Berk Prepares to Return as CEO , ... President Joel Seligman today announced that on March 1 ... full-time CEO of the Medical Center while Mark B. Taubman ... of Rochester School of Medicine and Dentistry .   , "I am excited ...
... will be held in Barcelona, Spain (Centre Convencions Internacional ... 24 - Saturday 27 March 2010. The ... the only one that involves all the major players ... between clinicians, scientists and patients in a partnership of ...
... survivors wait up to five years before disclosing they were ... Montral, the Universit du Qubec Montral and the Universit ... . "The number of victims who never reveal their ... very high," says co-author Mireille Cyr, a psychology professor of ...
... closely supported by a nurse-physician primary care team are twice ... those who receive usual care, according to a study by ... The research, published online in the latest edition of the ... 18 months of a randomized controlled trial, Guided Care recipients ...
Cached Medicine News:Health News:Obesity Action Coalition Calls on Insurers and Employers to Increase Access to Childhood Obesity Treatments Based on Recent United States Preventative Task Force Recommendations 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 2Health News:Watson Confirms Filing of FDA Application for Generic Lidoderm(R) 3Health News:New Dean of School of Medicine and Dentistry Announced 2Health News:New Dean of School of Medicine and Dentistry Announced 3Health News:Disclosing sexual abuse is critical 2Health News:Guided Care participants rate quality of health care high 2
Disposable Feather Blades, 50 per pack...
Knife sharpening back for Standard Knife, C Profile...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
Medicine Products: